What is the optimal treatment for obese patients with advanced ovarian carcinoma?

American Journal of Obstetrics and Gynecology

Volumn 211, Issue 3, 2014, Pages 231.e1-231.e9

  Worley, Michael J ^a   Guseh, Stephanie H ^a   Rauh Hain, J Alejandro ^b   Esselen, Katharine M ^a   Muto, Michael G ^a   Feltmate, Colleen M ^a   Berkowitz, Ross S ^a   Del Carmen, Marcela G ^b   Schorge, John O ^b   Horowitz, Neil S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

neoadjuvant chemotherapy; obesity; ovarian cancer; primary debulking surgery

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEOADJUVANT CHEMOTHERAPY WITH INTERVAL DEBULKING SURGERY; OBESE PATIENT; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT; PERITONEUM TUMOR; PNEUMONIA; POSTOPERATIVE ILEUS; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PREOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SMALL INTESTINE OBSTRUCTION; UTERINE TUBE CARCINOMA; WOUND COMPLICATION;

NEOADJUVANT CHEMOTHERAPY; OBESITY; OVARIAN CANCER; PRIMARY DEBULKING SURGERY;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OBESITY; OVARIAN NEOPLASMS;

EID: 85058204930     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2014.03.059     Document Type: Article

References (41)

1. K.M. Flegal, M.D. Carroll, C.L. Ogden, and C.L. Johnson Prevalence and trends in obesity among US adults, 1999-2000 JAMA 288 2002 1723 1727
2. K.M. Flegal, M.D. Carroll, C.L. Ogden, and L.R. Curtin Prevalence and trends in obesity among US adults, 1999-2008 JAMA 303 2010 235 241
3. H. Kuper, D.W. Cramer, and L. Titus-Ernstoff Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status? Cancer Causes Control 13 2002 455 463
4. M.F. Leitzmann, C. Koebnick, and K.N. Danforth et al. Body mass index and risk of ovarian cancer Cancer 115 2009 812 822
5. L.J. Schouten, C. Rivera, and D.J. Hunter et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies Cancer Epidemiol Biomarkers Prev 17 2008 902 912
6. A.A. Secord, and P.A. Gehrig Obesity: too big a problem to ignore Gynecol Oncol 126 2012 274 276
7. J.P. Adams, and P.G. Murphy Obesity in anaesthesia and intensive care Br J Anaesth 85 2000 91 108
8. G. Dominguez-Cherit, R. Gonzalez, D. Borunda, J. Pedroza, J. Gonzalez-Barranco, and M.F. Herrera Anesthesia for morbidly obese patients World J Surg 22 1998 969 973
9. A.J. Wolfberg, F.J. Montz, and R.E. Bristow Role of obesity in the surgical management of advanced-stage ovarian cancer J Reprod Med 49 2004 473 476
10. C. Fotopoulou, R. Richter, and E.I. Braicu et al. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking Ann Surg Oncol 18 2011 2629 2637
11. S.V. Barrett, J. Paul, A. Hay, P.A. Vasey, S.B. Kaye, and R.M. Glasspool Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial Ann Oncol 19 2008 898 902
12. K.S. Matthews, J.M. Straughn Jr., M.K. Kemper, K.E. Hoskins, W. Wang, and R.P. Rocconi The effect of obesity on survival in patients with ovarian cancer Gynecol Oncol 112 2009 389 393
13. O.A. Bamgbade, T.W. Rutter, O.O. Nafiu, and P. Dorje Postoperative complications in obese and nonobese patients World J Surg 31 2007 556 561
14. M.J. Worley Jr., S.H. Guseh, and J.A. Rauh-Hain et al. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol 129 2013 69 73
15. J.A. Rauh-Hain, N. Rodriguez, and W.B. Growdon et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer Ann Surg Oncol 19 2012 959 965
16. P.E. Schwartz What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? Oncology (Williston Park) 22 2008 1118 1125 discussion 30, 32, 34
17. P.E. Schwartz Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer Curr Oncol Rep 11 2009 457 465
18. I. Vergote, C.G. Trope, and F. Amant et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
19. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 2009 2315 2320
20. U. Keil, and K. Kuulasmaa WHO MONICA project: risk factors Int J Epidemiol 18 1989 S46 S55
21. G.D. Aletti, S.C. Dowdy, K.C. Podratz, and W.A. Cliby Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer Am J Obst Gynecol 197 2007 676.e1 676.e7
22. M. Markman Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer Gynecol Oncol 131 2013 241 245
23. D.S. Chi, F. Musa, and F. Dao et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) Gynecol Oncol 124 2012 10 14
24. M.A. Glasgow, H. Yu, and T.J. Rutherford et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV) J Surg Oncol 107 2013 195 200
25. J.Y. Hou, M.G. Kelly, and H. Yu et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 2007 211 217
26. G.H. Lyman, D.C. Dale, and J. Crawford Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 2003 4524 4531
27. J.J. Griggs, and M.S. Sabel Obesity and cancer treatment: weighing the evidence J Clin Oncol 26 2008 4060 4062
28. J.J. Griggs, M.E. Sorbero, and G.H. Lyman Undertreatment of obese women receiving breast cancer chemotherapy Arch Intern Med 165 2005 1267 1273
29. G.H. Lyman Impact of chemotherapy dose intensity on cancer patient outcomes J Natl Compr Canc Netw 7 2009 99 108
30. G.H. Lyman, D.C. Dale, J. Friedberg, J. Crawford, and R.I. Fisher Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study J Clin Oncol 22 2004 4302 4311
31. M. Shayne, E. Culakova, and M.S. Poniewierski et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy Cancer 110 2007 1611 1620
32. K.M. Field, S. Kosmider, and M. Jefford et al. Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey J Oncol Pract 4 2008 108 113
33. J.J. Griggs, P.B. Mangu, and H. Anderson et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 30 2012 1553 1561
34. R.F. Ozols, B.N. Bundy, and B.E. Greer et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
35. A.H. Calvert, D.R. Newell, and L.A. Gumbrell et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756
36. S.B. Duffull, and B.A. Robinson Clinical pharmacokinetics and dose optimisation of carboplatin Clin Pharmacokinet 33 1997 161 183
37. M.J. Egorin, L.M. Reyno, and R.M. Canetta et al. Modeling toxicity and response in carboplatin-based combination chemotherapy Semin Oncol 21 1994 7 19
38. B.T. Sorensen, A. Stromgren, P. Jakobsen, and A. Jakobsen Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients Cancer Chemother Pharmacol 28 1991 397 401
39. A. Jakobsen, K. Bertelsen, and J.E. Andersen et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study J Clin Oncol 15 1997 193 198
40. J.D. Wright, C. Tian, and D.G. Mutch et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 109 2008 353 358
41. M.A. Bookman, M.F. Brady, and W.P. McGuire et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 2009 1419 1425